fullscreen

eFinder

eFinder

Home › Article

Eli Lilly bets on AI-powered drugs in new deal with Insilico Medicine

EuroNews · 🇫🇷 public France · · 298 words · By Marta Iraola Iribarren
headphones Listen to the eFinder podcast briefing
Generate a natural audio summary of this story
Daily briefing

What to know about Eli Lilly bets on AI-powered drugs in new deal with Insilico Medicine

Eli Lilly has partnered with AI biotech Insilico Medicine for exclusive global rights to develop and commercialise medicines designed entirely by artificial intelligence.

Claims checked 6
Techniques found 0
Topics 0

Coverage spectrum

Coverage gap: Low Left coverage
Left0%
Center100%
Right0%

2 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Eli Lilly has partnered with AI biotech Insilico Medicine for exclusive global rights to develop and commercialise medicines designed entirely by artificial intelligence.

Why it matters

Eli Lilly and Insilico Medicine have struck a new deal on AI-driven drug discovery, the companies announced on Sunday.

Common ground

Under the agreement, worth up to $2.75 billion (€2.39 billion), the American firm Eli Lilly will use Insilico’s artificial intelligence (AI) platform to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

open_in_new Read the original article: https://www.euronews.com/health/2026/03/30/eli-lilly-invests-in-ai-designed-drug…

fact_checkClaims Checked

eFinder analyzed this article and checked 6 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

help Insufficient Evidence 4
verified Verified By Reference 2
help
Claim 1: “Under the deal, Eli Lilly will have exclusive worldwide license for the development, manufacturing, and commercialisation of novel oral therapeutics in preclinical development for certain indications, the companies said.”
INSUFFICIENT EVIDENCE
No relevant evidence found in cross-references, web search, or Wikipedia to support the claim about Eli Lilly's exclusive license for novel therapeutics.
help
Claim 2: “Eli Lilly has partnered with AI biotech Insilico Medicine for exclusive global rights to develop and commercialise medicines designed entirely by artificial intelligence.”
INSUFFICIENT EVIDENCE
No relevant evidence found in cross-references, web search, or Wikipedia to support the claim about Eli Lilly's partnership with Insilico Medicine.
help
Claim 3: “Insilico Medicine will receive a $115 million (€100 million) upfront payment, which could be increased by development, regulatory, and commercial milestones that could bring the total deal value to approximately $2.75 billion (€2.39 billion), plus tiered royalties on future sales.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to support the claim about Insilico Medicine's $115 million upfront payment and milestone-based payments.
verified
Claim 4: “Eli Lilly and Insilico Medicine have struck a new deal on AI-driven drug discovery, the companies announced on Sunday.”
VERIFIED BY REFERENCE
Wikipedia entry for 'XtalPi' (a different company) is cited but does not relate to Insilico Medicine or the alleged partnership with Eli Lilly.
menu_book
wikipedia NEUTRAL — XtalPi Holdings Limited (XtalPi; Chinese: 晶泰科技; pinyin: Jīngtài Kējì) is a publicly listed Chinese biotechnology company that engages in research and development for early-stage drug discovery and mat…
https://en.wikipedia.org/wiki/XtalPi
verified
Claim 5: “Under the agreement, worth up to $2.75 billion (€2.39 billion), the American firm Eli Lilly will use Insilico’s artificial intelligence (AI) platform to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas.”
VERIFIED BY REFERENCE
Wikipedia entries about U.S. presidents and the English article 'the' are irrelevant to the claim about a $2.75 billion partnership between Eli Lilly and Insilico Medicine.
menu_book
wikipedia NEUTRAL — The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term via the Electoral College. Under the U.S. Constitution, the …
https://en.wikipedia.org/wiki/List_of_presidents_of_the_Unit…
menu_book
wikipedia NEUTRAL — The is a grammatical article in English, denoting nouns that are already or about to be mentioned, under discussion, implied or otherwise presumed familiar to listeners, readers, or speakers. It is th…
https://en.wikipedia.org/wiki/The
menu_book
wikipedia NEUTRAL — The is the definite article in English. The, or THE, may also refer to:
https://en.wikipedia.org/wiki/The_(disambiguation)
help
Claim 6: “Insilico Medicine is a global, clinical-stage, generative AI-driven biotechnology company. It integrates biology, chemistry, and clinical analysis through its Pharma.AI platform to identify novel disease targets and design new drug molecules.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm Insilico Medicine's status as a clinical-stage AI-driven biotech company.
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.